BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azim HA, Omar A, Atef H, Zawahry H, Shaker MK, Abdelmaksoud AK, EzzElarab M, Abdel-Rahman O, Ismail M, Kassem L, Waked I. Sorafenib plus tegafur-uracil (UFT) vs sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). J Hepatocell Carcinoma. 2018;5:109-119. [PMID: 30510922 DOI: 10.2147/jhc.s169285] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
2 Han Y, Zhi WH, Xu F, Zhang CB, Huang XQ, Luo JF. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. World J Gastroenterol 2021; 27(19): 2415-2433 [PMID: 34040331 DOI: 10.3748/wjg.v27.i19.2415] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
3 Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sasaki R, Kanda T, Yokosuka O, Kato N, Matsuoka S, Moriyama M. Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. Int J Mol Sci 2019;20:E1406. [PMID: 30897788 DOI: 10.3390/ijms20061406] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
5 Meyers BM, Knox JJ, Cosby R, Beecroft J, Chan KK, Coburn N, Feld JJ, Jonker D, Mahmud A, Ringash J. Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. CanLivJ 2021;4:257-74. [DOI: 10.3138/canlivj-2020-0039] [Reference Citation Analysis]
6 Wu J, Xue R, Jiang RT, Meng QH. Characterization of metabolic landscape in hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(9): 1144-1156 [PMID: 34616519 DOI: 10.4251/wjgo.v13.i9.1144] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
8 Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W, Guo C. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:126. [PMID: 32631382 DOI: 10.1186/s13046-020-01629-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 11.5] [Reference Citation Analysis]